CPIX — CUMBERLAND PHARMACEUTICALS INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1087294 ·
Last close
$5.80
Market Cap
$86.96M
52W High
$9.28
52W Low
$1.43
ADV30
176,556
Next earnings
2026-11-10
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 166,458 — -3,160,461 -4,276,377 62,879,694 3,862,402 45,773,246
Mar 2026 9,131,317 7,197,428 -3,129,292 -3,289,639 70,995,020 11,007,245 49,692,008
Dec 2025 13,678,651 11,437,307 -1,371,202 -1,411,692 76,823,992 11,444,693 52,279,770

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$2,135,020
Investing CF
$-6,463,987
Financing CF
$-7,025,108
CapEx
$-1,897,777
Dividends Paid
—
Buybacks
$-71,440
EPS Diluted TTM
$4.49
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-34,370,075
Inventory
$29,935
Receivables
$13,419,594
ST Investments
—
EBIT TTM
$-9,263,750
Pretax Income TTM
$-9,572,954
Interest Exp TTM
$309,204
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$46,288,848
EBITDA
$1,972,377
Free Cash Flow
$4,552,190
Enterprise Value
$11,841,683
Total Cash
$80,581,024
Total Debt
$4,595,768
Shares Out
14,992,812
Trailing EPS
$-0.57
Book Value
$4.84
ROE
-3.4%
ROA
-1.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 44,521,431 -2,791,993 -2,836,128 76,823,992 52,279,770 24,880,322 4,932,522
Dec 2024 37,867,945 -6,432,409 -6,479,770 75,583,410 53,037,433 22,853,494 -612,186
Dec 2023 39,552,507 -9,554,661 -6,279,320 81,776,075 52,516,206 29,603,441 6,093,821
Dec 2022 42,010,949 -5,704,929 -5,570,241 92,925,158 56,951,152 36,266,132 8,453,396

TTM Snapshot

Revenues TTM
$31,268,788
NetIncome TTM
$-10,918,472
OpCashFlow TTM
—
Assets (Latest)
$62,879,694
Forward EPS
$0.14

Max Pain — expiry 2027-01-15

max pain strike: $5.00 · spot: $6.57 · call oi: 1,602 · put oi: 1,032
Expected Move to 2027-01-15: ±$2.70 (41.10%) — implied range $3.87 – $9.27 · ATM straddle on $6.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RVRC Revium Rx. $86.84M $1.43 —
DERM Journey Medical Corp $86.70M $3.90 —
HURA TuHURA Biosciences, Inc./NV $89.22M $1.40 —
NKTX Nkarta, Inc. $89.53M $1.25 —
GNLX GENELUX Corp $90.49M $2.00 —

News headlines (Yahoo Finance, 1h cache)

Cumberland Pharmaceuticals Q3 Earnings Call Highlights
2026-11-11 00:14 · Yahoo
Cumberland: Q3 Earnings Snapshot
2026-11-10 21:08 · Yahoo
CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE
2026-11-10 21:00 · Yahoo
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q3 2026 FINANCIAL RESULTS
2026-11-03 21:05 · Yahoo
Cumberland Pharmaceuticals Begins Rolling FDA NDA for Dyscorban in Duchenne Cardiomyopathy
2026-10-26 22:02 · Yahoo
CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM
2026-10-26 20:40 · Yahoo
Cumberland Pharmaceuticals stock tumbles on trial results
2026-10-23 21:08 · Yahoo
Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results
2026-10-23 20:05 · Yahoo
CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL
2026-10-23 13:05 · Yahoo
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
2026-07-28 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.